Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.

ABSTRACT:

Background & aims

Short duration treatment may aid HCV elimination among key populations. This study evaluated the efficacy of glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection.

Methods

In this single-arm multicentre international trial, adults with recent HCV (duration of infection <12 months) received glecaprevir-pibrentasvir 300 mg-120 mg daily for 4 weeks. Primary infection was defined as a first positive anti-HCV antibody and/or HCV RNA measurement within 6 months of enrolment and either acute clinical hepatitis within 12 months (symptomatic illness or alanine aminotransferase >10x the upper limit of normal) or antibody seroconversion within 18 months. Reinfection was defined as new positive HCV RNA within 6 months and prior clearance (spontane

SUBMITTER: Martinello M 

PROVIDER: S-EPMC10522905 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature